Listed by the USPTO as SZNAIDMAN, MARCOS L
Tech Center 1600 • Art Units: 1611 1612 1623 1628 1629
This examiner grants 37% of resolved cases
SZNAIDMAN, MARCOS L works in Tech Center 1600 and art unit 1611. The record includes 1278 resolved cases, a 37.4% allowance rate, and a 16.1% interview lift. The median time to allowance is 1303 days. The large case record supports attention to the relatively limited allowance outcome and extended timing, while interviews offer a possible but not dominant prosecution tool.
The leading companies are Vanderbilt University, Provibio Co. Ltd., and Deciphera Pharmaceuticals LLC. The listed firms are Conley Rose, P.C., COOLEY LLP, and FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER. These organizations provide institutional and pharmaceutical context for assessing the examiner’s recorded work.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19548797 | PDK1 REGULATORY COMPOUND AND COMPOSITION CONTAINING THE SAME | Non-Final OA | PROVIBIO CO., LTD. |
| 18872672 | COMPOSITIONS COMPRISING DISODIUM 5,10-METHYLENE-(6R)-TETRAHYDROFOLATE | Non-Final OA | MERCK PATENT GMBH |
| 18373418 | COMPOSITIONS AND METHODS FOR IMPROVING CARDIAC STRUCTURE AND/OR FUNCTION | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18353069 | Combination Therapeutics Comprising Nrf2 Agonists and Antivirals for Treating Viral Infections | Non-Final OA | The Regents of the University of California |
| 18691641 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Vanderbilt University |
| 18691617 | HETEROARYL-LINKED ANALOGS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Vanderbilt University |
| 18452885 | Use of Histamine Antagonists and Glucocorticoid for Treating and Preventing Neurodegenerative Diseases | Final Rejection | City University of Hong Kong |
| 18604733 | N,N'-DIPHENYL-4,4'-BIPHENYLDICARBOXAMIDE ANALOGS AND THEIR USE IN CANCER TREATMENT | Non-Final OA | Board of Regents, The University of Texas System |
| 18363429 | NERVE AGENT DECONTAMINATING AGENTS | Non-Final OA | THE CURATORS OF THE UNIVERSITY OF MISSOURI |
| 18275731 | SELECTIVE ROCK2 INHIBITION FOR TREATMENT OF EDEMA AND ASSOCIATED CONDITIONS | Final Rejection | Trustees of Boston University |
| 18263211 | ANTIPARASITIC COMPOUNDS | Final Rejection | Intervet Inc. |
| 18028618 | USE OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | Final Rejection | LG CHEM, LTD. |
| 18329957 | METHODS OF TREATING DISEASES AND DISORDERS ASSOCIATED WITH CALCIUM ION SIGNALING | Final Rejection | Temple University-Of the Commonwealth System of Higher Education |
| 18566249 | PYRIDAZINES OR 1,2,4-TRIAZINES SUBSTITUTED BY SPIROCYCLIC AMINES | Non-Final OA | Janssen Pharmaceutica NV |
| 18691426 | TREATMENT OF SLEEP DISTRUBANCES IN AUTISM SPECTRUM DISORDER PATIENTS | Non-Final OA | Vanda Pharmaceuticals Inc. |
| 18703712 | NITROGEN-CONTAINING TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Non-Final OA | Shanghai Hengrui Pharmaceutical Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy37.4% of resolved applications examined by Marcos L Sznaidman were allowed (1,278 resolved cases), compared with 35.0% across Art Unit 1611 over the last five years.
This examiner's interview lift is +16.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Marcos L Sznaidman took 1,303 days on average from filing to allowance.
Marcos L Sznaidman examines applications in Art Unit 1611 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
